<DOC>
	<DOC>NCT01541618</DOC>
	<brief_summary>The purpose of this study is to compare biomarker levels in Multiple Sclerosis (MS) patients before and after beginning Natalizumab.</brief_summary>
	<brief_title>A Study of MSDx Complex 1 as a Marker for Therapy Response in Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
	<criteria>1. Diagnosis of clinically definite relapsing remitting MS (RRMS) 2. Age 45 years and older 3. Willing and able to provide written informed consent 4. Patient has high disease activity. 5. Patient is about to begin Natalizumab (Tysabri) therapy. 1. Any clinically significant disease other than MS that is likely to interfere with the evaluation of CDMS 2. Known infectious or hematological disease. 3. Unwilling or unable to comply with the requirements of this protocol 4. Subject can not have a gadolinium enhanced MRI</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>MS</keyword>
	<keyword>RRMS</keyword>
	<keyword>RR Multiple Sclerosis</keyword>
</DOC>